Exploring the Crossroads of Cannabis and Psychiatry

Cannabis, like many other recreational drugs, has seen a rapid rise in use. Once an outlawed substance, it has now transformed into a $61 billion commercial industry, with some cannabis-derived medications receiving US Food and Drug Administration approval. Additionally, it is likely to be rescheduled by the Drug Enforcement Administration. Over the past decade, cannabis research has exploded, with more than 35,000 publications, averaging around 4000 new studies each year.

Despite this surge in research, psychiatry has been somewhat slow in integrating cannabis into its domain. Given the unique properties of cannabis compared to other substances like psychedelics, psychiatry has an opportunity to explore its therapeutic potential while carefully weighing the risks. Entering this field presents challenges, but the potential rewards make this exploration worthwhile.

The American Psychiatric Association released a new textbook on cannabis, which comprehensively examines its potential detrimental effects. This highlights the need for a balanced approach—one that considers both the therapeutic benefits and the risks associated with cannabis use in mental health treatment.

As clinicians navigate cannabis’ evolving role in psychiatry, they must critically evaluate its place in modern medicine. By staying informed and open to emerging research, clinicians can ensure they are make evidence-based decisions for the benefit of our patients and the field at large.

Dr Viner is a practicing physician who has been working with psychiatric patients in the state of Nevada for over ten years. He serves as a Clinical Professor of Psychiatry and Behavioral Sciences at the University of Nevada School of Medicine.